High Dose Vitamin D Did Not Improve Outcomes in Metastatic…

High Dose Vitamin D Did Not Improve Outcomes in Metastatic Colorectal Cancer, Major Trial Finds Earlier research had suggested that higher vitamin D levels might improve survival in cancer patients, raising real hope that adding high dose vitamin D3 to standard chemotherapy could meaningfully benefit patients with metastatic colorectal cancer, a condition with historically limited treatment options and poor outcomes. A large phase 3 trial published in JAMA now provides a clear, rigorously tested answer. The trial: The SOLARIS trial, conducted across 151 academic and community centres in the United States, enrolled 455 adults with previously untreated, unresectable metastatic colorectal cancer. Patients were randomly assigned in a double blind design to receive either high dose vitamin D3, 8,000 IU daily as a loading dose followed by 4,000 IU daily, or standard dose vitamin D3 at 400 IU daily. All patients received standard chemotherapy, either FOLFOX or FOLFIRI regimens, plus bevacizumab. The primary result, no meaningful difference: At a median follow up of 20 months, median progre